Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc KNBIF


Primary Symbol: V.KNE

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by MirrorWorldManon Nov 15, 2024 2:05pm
23 Views
Post# 36315369

RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel

RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound GelThis is an important milestone that allows a launch of a new product to Canadian consumers and a chance to demonstrate a working model for future commercializations.   I have always been a firm believer that a BioTech must not stop at the responsibility of discovering and developing up scale of a new product but also must understand it is their obligation to see it gets into the hands of the consumer.   Lets hope that the marketing and sales divisions ramp up quickly. Marc shoul of already developed materials in preparation. The first 9 months post launch are critical and an impactful plan must be in place
<< Previous
Bullboard Posts
Next >>